Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic ER+ Her2- Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT02753686
What this trial is testing

Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy

Who this might be right for
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Novartis Pharmaceuticals 440
Testing effectiveness (Phase 2)Looking for participantsNCT07222215
What this trial is testing

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Who this might be right for
Estrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more
Kristina A. Fanucci 297
Early research (Phase 1)UnknownNCT05957939
What this trial is testing

Targeting Metastatic Breast Cancers by Alkaline Glucosodiene Molecules Via a Metabolic Pathway Phase I Clinical Trial

Who this might be right for
TNBC - Triple-Negative Breast Cancer
Ministry of Health, Saudi Arabia 2
Testing effectiveness (Phase 2)Ended earlyNCT02457910
What this trial is testing

Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
Vanderbilt-Ingram Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT02069093
What this trial is testing

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 92
Testing effectiveness (Phase 2)Study completedNCT02630693
What this trial is testing

Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Canadian Cancer Trials Group 180
Testing effectiveness (Phase 2)Study completedNCT03250676
What this trial is testing

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Who this might be right for
Breast NeoplasmsBreast CancerEstrogen-receptor Positive Breast Cancer+5 more
Eisai Inc. 151
Not applicableStudy completedNCT06525675
What this trial is testing

Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study)

Who this might be right for
Metastatic Breast CancerAdvanced Breast CancerLuminal Breast Cancer+2 more
MedSIR 419
Testing effectiveness (Phase 2)Study completedNCT02599194
What this trial is testing

18F-FSPG PET/CT for Cancer Patients on Therapy

Who this might be right for
B-Cell NeoplasmEstrogen Receptor NegativeHER2/Neu Negative+13 more
Andrei Iagaru 7
Testing effectiveness (Phase 2)Ended earlyNCT00597597
What this trial is testing

Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Rush University Medical Center 11
Testing effectiveness (Phase 2)Ended earlyNCT00759642
What this trial is testing

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Who this might be right for
Metastatic Breast Cancer
University of Kansas Medical Center 33
Large-scale testing (Phase 3)Study completedNCT02278120
What this trial is testing

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

Who this might be right for
Advanced Metastatic Breast Cancer
Novartis Pharmaceuticals 672
Testing effectiveness (Phase 2)Study completedNCT00483223
What this trial is testing

Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response

Who this might be right for
Breast Cancer
Massachusetts General Hospital 86
Large-scale testing (Phase 3)Study completedNCT03079011
What this trial is testing

PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection

Who this might be right for
Metastatic Breast Cancer
UNICANCER 1,017
Early research (Phase 1)Study completedNCT01320592
What this trial is testing

PD0332991/Paclitaxel in Advanced Breast Cancer

Who this might be right for
Breast Cancer
Abramson Cancer Center at Penn Medicine 28
Early research (Phase 1)Study completedNCT01226316
What this trial is testing

Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules

Who this might be right for
Advanced Solid MalignancySafety and TolerabilityPharmacokinetics+11 more
AstraZeneca 285
Testing effectiveness (Phase 2)Looking for participantsNCT06665178
What this trial is testing

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

Who this might be right for
Breast Cancer
British Columbia Cancer Agency 20
Early research (Phase 1)Study completedNCT01791478
What this trial is testing

BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-negative Breast CancerInvasive Ductal Breast Carcinoma+3 more
Vanderbilt-Ingram Cancer Center 46
Testing effectiveness (Phase 2)Ended earlyNCT01697293
What this trial is testing

PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer

Who this might be right for
Breast AdenocarcinomaEstrogen Receptor PositiveHER2/Neu Negative+6 more
Prescient Therapeutics, Ltd. 34
Large-scale testing (Phase 3)WithdrawnNCT06585969
What this trial is testing

A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerLuminal B+2 more
Danish Breast Cancer Cooperative Group
Next Page